US Stock Insider Trading | Opus Genetics disclosed one insider transaction on February 17

2026-02-20 21:34:20

On February 17, 2026, Opus Genetics (IRD) disclosed one insider transaction. Executive Jayagopal Ashwath sold 5,313 shares on February 12, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 17, 2026	Executive	Jayagopal Ashwath	February 12, 2026	Sell	5313	3.39	18,000
January 21, 2026	Executive	Zaremba Rabourn Amy	January 18, 2026	Sell	3390	2.10	7,119.00
January 13, 2026	Executive	Zaremba Rabourn Amy	January 10, 2026	Sell	3950	1.93	7,623.50
December 31, 2025	Director	Gallagher Cam	December 29, 2025	Buy	81,000	1.98	160,300
December 31, 2025	Director	Gallagher Cam	December 29, 2025	Buy	83,000	1.97	163,400
December 11, 2025	Director	Foundation Fighting Blindness Retinal Degeneration Fund	December 9, 2025	Sell	4,000,000	2.15	8,600,000
November 4, 2025	Director	Magrath George	November 1, 2025	Sell	30,400	2.30	6,980
October 24, 2025	Director	YERXA BENJAMIN R	October 22, 2025	Sell	23,800	1.95	4,640
August 27, 2025	Director	Ainsworth Sean, Gallagher Cam	August 25, 2025	Buy	956,500	1.15	1,100,000
February 18, 2025	Executive	Jayagopal Ashwath	February 13, 2025	Sell	5,193	1.15	5,971.95

[Company Information]

Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company dedicated to developing and commercializing therapies for various eye diseases. Ocuphire’s product pipeline currently includes two small-molecule candidates targeting ocular indications. The company’s lead candidate, Nyxol eye drops, is a preservative-free formulation of phentolamine mesylate administered once daily, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. It is under development for several indications, including low-light or night vision impairment, pharmacologic mydriasis, and presbyopia. Ocuphire’s second candidate, APX3330, is an oral tablet taken twice daily, aimed at inhibiting angiogenesis and inflammation pathways associated with retinal and choroidal vascular diseases such as diabetic retinopathy and diabetic macular edema.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.